MedTrace Logo

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

NCT02936037 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 642

Last updated 2020-11-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.

Conditions

Interventions

DRUG

MD1003 100mg capsule

DRUG

PLACEBO

an inactive substance

Sponsors & Collaborators

  • MedDay Pharmaceuticals SA

    lead INDUSTRY

Principal Investigators

  • Bruce Cree, MD, PHD · University of California, San Francisco

  • Frederic Sedel, MD, PHD · Medday Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-11-15
Completion
2020-04-23

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Czechia
  • Germany
  • Hungary
  • Italy
  • Poland
  • Spain
  • Sweden
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02936037 on ClinicalTrials.gov